Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.72 |
| ▸ | EGFR | P00533 | 19/20 | 0.71 |
| ▸ | KDR | P35968 | 2/20 | 0.68 |
| ▸ | AURKA | O14965 | 1/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.68 |
| ▸ | INSR | P06213 | 1/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.68 |
| ▸ | FLT4 | P35916 | 1/20 | 0.68 |
| ▸ | CLK1 | P49759 | 1/20 | 0.68 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.68 |
| ▸ | TEK | Q02763 | 1/20 | 0.68 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18012076 | 0.95 | EGFR (0.79) | FBP1EGFRKDRAURKAERBB2 | |
| SCHEMBL18012883 | 0.92 | EGFR (0.71) | FBP1EGFRKDRAURKAERBB2 | |
| SCHEMBL19125531 | 0.90 | FBP1 (0.62) | FBP1EGFRKDRAURKAERBB2 | |
| SCHEMBL19885305 | 0.88 | EGFR (0.58) | FBP1EGFRKDRAURKAERBB2 | |
| SCHEMBL18013064 | 0.87 | EGFR (0.81) | EGFRKDRERBB2PDGFRBFLT4 | |
| SCHEMBL22338174 | 0.87 | EGFR (0.80) | FBP1EGFRKDRAURKAERBB2 | |
| SCHEMBL25083284 | 0.87 | EGFR (0.71) | FBP1EGFRKDRAURKAERBB2 | |
| SCHEMBL15217652 | 0.87 | FBP1 (0.78) | FBP1EGFRKDRAURKAERBB2 | |
| SCHEMBL29577315 | 0.87 | FBP1 (0.78) | FBP1EGFRKDRAURKAERBB2 | |
| SCHEMBL29577645 | 0.87 | FBP1 (0.78) | FBP1EGFRKDRAURKAERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| WO-2016123706-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | EGFR, ERBB2, ERBB4 | FBP1 213/4885EGFR 1/4885KDR 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.